Natural Alternatives International Reports Q4 Net Loss of $7.2M, Net Sales of $33.9M
ByAinvest
Tuesday, Sep 23, 2025 4:31 pm ET1min read
NAII--
Despite the net loss, Q4 net sales increased 15% to $33.9 million, with private-label contract manufacturing sales up 15% to $31.8 million and CarnoSyn® beta-alanine sales increasing 14% to $2.1 million. For full fiscal 2025, net sales grew 14% to $129.9 million, though the company recorded a net loss of $13.6 million, or $2.28 per diluted share, compared to a $7.2 million loss in 2024 [1].
The primary challenges faced by the company were underutilization of factory capacity, tax valuation allowances, and litigation costs. Gross margin improved to 10.4% in Q4 2025 from 4.8% in Q4 2024, indicating better operational efficiency. Management's guidance is cautiously optimistic, projecting continued losses in the first half of fiscal 2026 but returning to profitability in the second half and for the full year, driven by anticipated significant sales growth and improved capacity utilization [1].
As of June 30, 2025, NAII maintained $12.3 million in cash and $30.5 million in working capital, with $8 million in unused borrowing capacity. The company's liquidity position remains stable, though working capital decreased from $38.1 million in 2024 to $30.5 million in 2025 [1].
The company's CEO, Mark A. Le Doux, stated, “The results achieved in our final quarter of fiscal year 2025 were negatively impacted by non-cash charges associated with accounting treatment of deferred tax assets and a litigation settlement, however, the net results were still a disappointment. The fourth quarter and fiscal 2025 showed increases in revenues and our preliminary outlook for this next fiscal year shows some ‘green shoots’ emerging in renewed growth in current and new customer relationships” [1].
Natural Alternatives International reported a net loss of $7.2 million, or ($1.20) per diluted share, on net sales of $33.9 million for Q4 of fiscal 2025, compared to a net loss of $1.9 million in the prior year. Excluding non-recurring charges, the net loss would have been $1.0 million. Net sales increased 15% to $33.9 million, with private-label contract manufacturing sales up 15% to $31.8 million. The company's net loss for fiscal 2025 was $13.6 million, or ($2.28) per diluted share.
Natural Alternatives International (NASDAQ: NAII), a nutritional supplements manufacturer, reported a challenging fourth quarter (Q4) fiscal 2025, with a net loss of $7.2 million, or $1.20 per diluted share, on net sales of $33.9 million. This compares to a net loss of $1.9 million in Q4 2024. Excluding non-recurring charges, the adjusted net loss would have been approximately $1.0 million, indicating operational improvements despite ongoing challenges [1].Despite the net loss, Q4 net sales increased 15% to $33.9 million, with private-label contract manufacturing sales up 15% to $31.8 million and CarnoSyn® beta-alanine sales increasing 14% to $2.1 million. For full fiscal 2025, net sales grew 14% to $129.9 million, though the company recorded a net loss of $13.6 million, or $2.28 per diluted share, compared to a $7.2 million loss in 2024 [1].
The primary challenges faced by the company were underutilization of factory capacity, tax valuation allowances, and litigation costs. Gross margin improved to 10.4% in Q4 2025 from 4.8% in Q4 2024, indicating better operational efficiency. Management's guidance is cautiously optimistic, projecting continued losses in the first half of fiscal 2026 but returning to profitability in the second half and for the full year, driven by anticipated significant sales growth and improved capacity utilization [1].
As of June 30, 2025, NAII maintained $12.3 million in cash and $30.5 million in working capital, with $8 million in unused borrowing capacity. The company's liquidity position remains stable, though working capital decreased from $38.1 million in 2024 to $30.5 million in 2025 [1].
The company's CEO, Mark A. Le Doux, stated, “The results achieved in our final quarter of fiscal year 2025 were negatively impacted by non-cash charges associated with accounting treatment of deferred tax assets and a litigation settlement, however, the net results were still a disappointment. The fourth quarter and fiscal 2025 showed increases in revenues and our preliminary outlook for this next fiscal year shows some ‘green shoots’ emerging in renewed growth in current and new customer relationships” [1].
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet